Compare COUR & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COUR | MPLT |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2021 | 2025 |
| Metric | COUR | MPLT |
|---|---|---|
| Price | $5.80 | $13.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 7 |
| Target Price | $10.53 | ★ $32.67 |
| AVG Volume (30 Days) | ★ 4.0M | 553.7K |
| Earning Date | 04-23-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 39.22 | ★ 82.39 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $757,500,000.00 | N/A |
| Revenue This Year | $9.43 | N/A |
| Revenue Next Year | $6.40 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.04 | N/A |
| 52 Week Low | $5.00 | $9.10 |
| 52 Week High | $12.32 | $40.43 |
| Indicator | COUR | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 53.62 | 39.67 |
| Support Level | $5.12 | $12.24 |
| Resistance Level | $6.34 | $20.20 |
| Average True Range (ATR) | 0.26 | 0.94 |
| MACD | 0.01 | 0.89 |
| Stochastic Oscillator | 52.04 | 74.93 |
Coursera Inc is an online learning platform that connects learners, educators, and institutions with the goal of providing educational content that is affordable, accessible, and relevant. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The company operates through two reporting segments: Consumer and Enterprise. The majority of revenue is generated from the Consumer segment. The consumer segment targets individual learners seeking to obtain hands-on learning, gain valuable job skills, receive professional-level certifications, and otherwise increase their knowledge to start or advance their careers.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.